Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -92.08% is 56% above its 5-year average of -211.56%, near the high end of its 5-year range (-616.96%–-50.81%).
As of the fiscal period ended Tuesday, June 30, 2026. 47.84% above its 12-month average of -176.54%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -92.08%.
RETURN ON EQUITY (ROE)
-92.08%
RETURN ON EQUITY (ROE) AVG TTM
-176.54%
RETURN ON EQUITY (ROE) AVG 3Y
-272.68%
RETURN ON EQUITY (ROE) AVG 5Y
-211.56%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+47.84%
CURRENT VS 3Y AVG
+66.23%
CURRENT VS 5Y AVG
+56.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.56%
median of 500 covered companies
CURRENT VS SECTOR MEDIAN
-138.79%
vs the sector median at left
Acurx Pharmaceuticals, Inc.
Market Cap
$5.55M
Return on Equity (ROE)
-92.08%
TTM Avg
-176.54%
3Y Avg
-272.68%
5Y Avg
-211.56%
Market Cap
$5.35M
Return on Equity (ROE)
N/A
TTM Avg
383.38%
3Y Avg
131.31%
5Y Avg
101.98%
Market Cap
$5.33M
Return on Equity (ROE)
-156.77%
TTM Avg
-655.11%
3Y Avg
-353.82%
5Y Avg
-293.10%
Market Cap
$5.80M
Return on Equity (ROE)
-92.44%
TTM Avg
-28.72%
3Y Avg
10.69%
5Y Avg
23.75%
Market Cap
$5.29M
Return on Equity (ROE)
-248.66%
TTM Avg
-110.63%
3Y Avg
-33.84%
5Y Avg
-33.84%
Market Cap
$5.21M
Return on Equity (ROE)
-351.30%
TTM Avg
-321.98%
3Y Avg
-228.03%
5Y Avg
-177.46%
Market Cap
$5.21M
Return on Equity (ROE)
-225.57%
TTM Avg
-289.16%
3Y Avg
-245.03%
5Y Avg
-192.04%
Market Cap
$5.92M
Return on Equity (ROE)
-111.42%
TTM Avg
-84.56%
3Y Avg
-107.54%
5Y Avg
-308.31%
Market Cap
$5.98M
Return on Equity (ROE)
105.35%
TTM Avg
0.10%
3Y Avg
-37.77%
5Y Avg
-33.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | $5.55M | -92.08% | -176.54% | -272.68% | -211.56% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.35M | N/A | 383.38% | 131.31% | 101.98% |
| Alzamend Neuro Inc (ALZN)vs › | $5.33M | -156.77% | -655.11% | -353.82% | -293.10% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.80M | -92.44% | -28.72% | 10.69% | 23.75% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.29M | -248.66% | -110.63% | -33.84% | -33.84% |
| Imunon, Inc. (IMNN)vs › | $5.21M | -351.30% | -321.98% | -228.03% | -177.46% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.21M | -225.57% | -289.16% | -245.03% | -192.04% |
| Lucyd, Inc (LUCY)vs › | $5.92M | -111.42% | -84.56% | -107.54% | -308.31% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.98M | 105.35% | 0.10% | -37.77% | -33.57% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.10M | -4165.92% | 61.14% | -23.12% | -18.15% |
ROE
-92.1%
ROA
-68.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -92.08% |
| 2026-03-31 | -106.92% |
| 2025-12-31 | -151.21% |
| 2025-09-30 | -252.13% |
| 2025-06-30 | -280.37% |
| 2025-03-31 | -513.73% |
| 2024-09-30 | -616.96% |
| 2024-06-30 | -488.09% |
| 2024-03-31 | -267.61% |
| 2023-12-31 | -312.38% |
| 2023-09-30 | -323.37% |
| 2023-06-30 | -211.54% |
| 2023-03-31 | -232.06% |
| 2022-12-31 | -165.31% |
| 2022-09-30 | -117.37% |
| 2022-06-30 | -142.96% |
| 2022-03-31 | -130.44% |
| 2021-12-31 | -102.72% |
| 2021-09-30 | -78.54% |
| 2021-06-30 | -50.81% |
| 2021-03-31 | -194.05% |
| 2020-12-31 | -170.27% |
